SCHEDULE 13D/A: Onconetix Interim CEO Ralph Schiess Updates Stake Following RSU Grant and Proteomedix Acquisition Integration

Onconetix, Inc. has filed an amended Schedule 13D revealing that Interim CEO and Chief Science Officer Ralph Schiess's beneficial ownership now stands at 4.63% after receiving a grant of restricted stock units and the conversion of preferred stock related to the Proteomedix acquisition.

Summary

• Ralph Schiess, Interim CEO and Chief Science Officer of Onconetix, Inc., has updated his beneficial ownership stake in the company to 673,365 shares, representing 4.63% of the common stock.
• This update follows the conversion of 195,664 shares of Series B Convertible Preferred Stock into 489,160 common shares on September 24, 2024, after stockholder approval on September 5, 2024, and a 1-for-40 reverse stock split.
• Additionally, Mr. Schiess received a grant of 177,462 fully vested Restricted Stock Units (RSUs) on December 20, 2024, in exchange for options to purchase shares of Proteomedix AG.
• The initial acquisition of shares stemmed from the Share Exchange Agreement dated December 15, 2023, where Onconetix acquired Proteomedix AG, making it a wholly-owned subsidiary.
• Mr. Schiess ceased to be a beneficial holder of more than 5% of the Issuer's Common Stock on December 31, 2024.
• A lock-up agreement, restricting the sale or transfer of certain shares, expired on December 31, 2024.

Sentiment

Score: 6

Explanation: The document is largely factual, detailing changes in an insider's beneficial ownership due to previously announced corporate actions and compensation. The grant of fully vested RSUs is a positive for the individual, and the completion of the stock conversion process is a neutral-to-positive sign of integration progress. The drop below 5% ownership is a mathematical outcome of dilution and RSU grant, not necessarily negative.

Positives

• The grant of 177,462 fully vested Restricted Stock Units (RSUs) to Ralph Schiess indicates continued compensation and alignment of interests with the company's performance.
• The completion of the Series B Convertible Preferred Stock conversion and the reverse stock split signifies the finalization of key steps related to the Proteomedix AG acquisition.

Negatives

• Ralph Schiess's beneficial ownership percentage decreased to 4.63%, falling below the 5% threshold, which could be perceived as a reduction in a key insider's relative stake, although it is a result of dilution from the reverse split and RSU grant, not a sale.

Future Outlook

The document indicates that a lock-up agreement restricting the sale or transfer of certain shares held by Ralph Schiess expired on December 31, 2024, allowing for potential future liquidity, though no specific plans for sale are disclosed.

Management Comments

• "Ralph Schiess serves as the Interim Chief Executive Officer and Chief Science Officer of the Issuer and, as a result, may be asked to discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others."
• "Other than in connection with the prior PMX Acquisition and except as may be set forth herein, the Reporting Person has no current intention, plans or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D."

Industry Context

This filing is specific to an insider's ownership stake following a corporate acquisition (Proteomedix AG by Onconetix, Inc.) and compensation events. It does not provide broader industry trends or competitive analysis, but reflects the ongoing integration and compensation structures typical after M&A activities in the biotechnology or pharmaceutical sectors.

Corporate Governance

Legal Proceedings

• During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
• During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Related Party Transactions

• The Reporting Person acquired shares pursuant to a Share Exchange Agreement dated December 15, 2023, by and among the Issuer, Proteomedix AG, and all holders of Proteomedix capital stock, where the Issuer acquired all equity interests of Proteomedix AG, and Ralph Schiess was a holder of Proteomedix equity interests.
• Ralph Schiess received 177,462 fully vested RSUs on December 20, 2024, in exchange for options to purchase shares of Proteomedix AG, pursuant to the Share Exchange Agreement.

Stakeholder Impact

• Shareholders: The reverse stock split and conversion of preferred stock impact the share structure and potentially the per-share value. The change in an insider's beneficial ownership percentage provides transparency regarding management's stake.
• Employees: The grant of fully vested RSUs to a key executive (Ralph Schiess) is a form of compensation and aligns his interests with the company's long-term performance.

Key Dates

Keywords

Onconetix, Ralph Schiess, Proteomedix AG, Schedule 13D, beneficial ownership, common stock, restricted stock units, RSU, share exchange agreement, corporate governance, stock conversion, reverse stock split, lock-up agreement, insider ownership